Reduce serum phosphorus of hemodialysis patients maybe help to reduce intact-parathyroid hormone which was increased

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007632

Enrollment

Unknown

Registered

2015-12-22

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease(CKD 5D)

Interventions

experimental group:reduce serum phosphorus by oral medcine

control group:routine treatment without reduce serum phosphorus

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patient who were maintained hemodialysis over 3 months; 2. ages between 18-80 years old; 3. male or female; 4. serum phosphorus >1.8mmol/L; 5. intact-parathyroid hormone >300pg/dL; 6. Signed a letter of authorization for patients, allowing the use and disclosure of personal health information (or informed consent, if applicable).

Exclusion criteria

Exclusion criteria: 1. Patients of maintain hemodialysis less than 3 months; 2. Age less than 18 and over 80 years old; 3. Serum phosphorus <1.8mmol/L; 4. intact-parathyroid hormone <300pg/dL; 5. The patients whose refuse taking part in the trial; 6. Patients combined with tumour, active bleeding, infection and other acute inflammation; 7. Patients who maybe renal transplant or peritoneal dialysis or go to other hospital in half year; 8. Patients who die during trial.

Design outcomes

Primary

Measure	Time frame
intact-parathyroid hormone;Serum phosphorus;	—

Secondary

Measure	Time frame
serum calcium;	—

Countries

China

Contacts

Public ContactGuan Tianjun

guantianjun@aliyun.com+86 13950199068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026